- Spexis receives approval of an extension of the deadline for the publication of its 2023 annual report and audited financials until latest May 31, 2024.
- Spexis announces extension of moratorium, receipt of an additional payment related to the sale of a preclinical antibiotics program and reversion of the lonodelestat license from Santhera
- Spexis announces closing of sale of preclinical antibiotics program to Basilea
Key statistics
As of last trade, Spexis AG (SPEX:SWX) traded at 0.0588, 381.97% above the 52 week low of 0.0122 set on Nov 14, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.0586 |
---|---|
High | 0.0588 |
Low | 0.0522 |
Bid | 0.052 |
Offer | 0.0588 |
Previous close | 0.0588 |
Average volume | 81.70k |
---|---|
Shares outstanding | 67.66m |
Free float | 31.54m |
P/E (TTM) | -- |
Market cap | 3.98m CHF |
EPS (TTM) | -0.2547 CHF |
Data delayed at least 15 minutes, as of Apr 30 2024 16:34 BST.
More ▼